CHU de BESANCON
Besançon, 25030, France
NCT Number: NCT03837730
Sepsis is an acute pathology defined as an inappropriate response of the host to infection, resulting in the onset of organ failure (Quick SOFA ≥2, or SOFA ≥2). Septic shock is a sepsis associated with an elevation of lactate ≥ 2 mmol / l and an arterial hypotension requiring vasoactive drugs. Several studies highlighted that sepsis is associated with a plasma L-arginine deficiency. This deficiency induces a lower availability of L-arginine for multiple metabolic pathways including those involved in the synthesis of nitric oxide (NO) in the vascular endothelium via NO synthase. NO is the main endogenous vasodilator mediator, a lower synthesis induces a vascular and endothelial dysfunction that can promote the occurrence of an organic dysfunction during sepsis. Decrease in available NO was confirmed in patients with sepsis and appears correlated with severity.
L-arginine deficiency can have multiple origins:
* L-arginine deficiency resulting from a decrease in endogenous production from citrulline synthesized by the enterocytes. Such enterocyte dysfunction has been confirmed in patients with sepsis and is characterized biologically by elevated plasma levels of I-FABP (intestinal fatty acid binding protein - enterocyte-specific protein, cytolysis marker) and lower than that of citrulline (hypocitrullinemia, marker of lower activity). * L-arginine deficiency may also result from a catabolism increase via arginase activity increased. This ubiquitous enzyme, having 2 isoforms (Arg1 and Arg2), allows the synthesis of urea and ornithine from L-arginine. An increase in arginase activity would decrease the available reserves of L-arginine for NO synthesis.
The objectives of this work is to evaluate, in patients with severe sepsis or septic shock, the prognostic value of the plasma arginase activity and the plasma expression of 2 isoforms Arg1 and Arg2, their kinetics, and the link between activity / expression of arginase and enterocyte dysfunction.
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
Besançon, 25030, France
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: 28 days
activity / expression of plasma arginase at ICU admission and 28-day mortality rate from admission to intensive care
Time frame: during the first 7 days of ICU admission
3 points kinetic : admission, day 3 and day 7
Time frame: 28 days
at ICU admission and 28-day mortality rate from admission to intensive care
Centre Hospitalier Universitaire de Besancon
Other
Activity and Expression of Plasma Arginase in Patients With Severe Sepsis or Septic Shock as Prognostic Value
Acronym: CARS
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04114162
Edema, Infections
Besançon, France
View Trial DetailsNCT05960994
Critical Care, Intensive Care Units
São Paulo, Brazil
View Trial DetailsNCT06999863
Intensive Care Units
Nantes, France
View Trial DetailsNCT07087600
Critical Illness, Disease Attributes
Recife, Pernambuco, Brazil
View Trial Details